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E-mail address: gabriel.galea@bristol.ac.uk (G.L. GaSclerostin is a potent inhibitor of bone formation which is down-regulated by mechanical loading.
To investigate the mechanisms involved we subjected Saos2 human osteoblastic cells to short peri-
ods of dynamic strain and used quantitative reverse transcriptase polymerase chain reaction to
compare their responses to unstrained controls. Strain-induced Sost down-regulation was recapit-
ulated by cyclo-oxygenase-2-mediated PGE2, acting through the EP4 receptor, whereas strain-
related up-regulation of osteocalcin was mediated by the EP2 receptor. Strain-related Sost regula-
tion required extracellular signal-regulated kinase signaling, whereas osteocalcin required protein
kinase C. These ﬁndings indicate early divergence in the signaling pathways stimulated by strain and
establish PGE2/EP4 as the pathway used by strain to regulate Sost expression.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
The natural functional regulator of bone architecture is habitual
mechanical loading. Age- and estrogen deﬁciency-related failure of
the mechanisms involved is associated with bone loss and increase
in fragility fractures. This is characteristic of osteoporosis [1]. Oste-
oporosis is most commonly treated with anti-resorptives [2]. The
only licensed anabolic treatment is intermittent parathyroid hor-
mone (PTH) [3] thought to exert its osteogenic effect, at least in
part, through down-regulation of the Wnt/bone morphogenetic
protein (BMP) antagonist sclerostin [4]. Neutralizing antibodies
against sclerostin are in clinical trials [5].
Like PTH, bone loading down-regulates Sost/sclerostin expres-
sion within osteocytes [6–10], whereas unloading increases its
production [7,11]. Local control of sclerostin could therefore con-
tribute to the mechanism by which loading regulates bone mass.
This is consistent with sclerostin knockout mice having high bone
mass and being resistant to unloading-induced bone loss [12].al Societies. Published by Elsevier
one morphogenetic protein;
2510; qRT-PCR, quantitative
KA, protein kinase A; PKC,
ed kinase; MAPK, mitogen
ciences, University of Bristol,
lea).To elucidate the early mechanisms by which loading regulates
sclerostin expression we sought to establish the role of cyclo-oxy-
genase (Cox)-2/prostaglandin (PG) signaling, which is an early
component of bone cells’ response to mechanical strain [13–16].
2. Materials and methods
2.1. Choice of cells
Human osteoblastic Saos2 cells (ECACC Cat. No. 89050205) ex-
press a differentiated phenotype [17] and have been used to study
Sost expression [18].
2.2. Reagents and cell culture
PGE2, AH6809 and AH23848 were from Sigma–Aldrich (Poole,
UK). NS398, TCS2510 (TCS), H89, calphostin C, and PD98059 were
from Tocris Bioscience (Bristol, UK). Saos2 cells were maintained in
phenol red-free DMEM containing 10% heat-inactivated FCS, 2 mM
L-glutamine, 100 IU/ml penicillin and 100 IU/ml streptomycin in a
37 C incubator at 5% CO2, 95% humidity.
2.3. Straining cells in vitro
Cells were seeded on custom-made plastic strips at an initial
density of 40 000 cells/cm2 in complete medium and allowed toB.V. Open access under CC BY-NC-ND license.
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stripped 2% FCS for 24 h prior to strain or treatment. Strain was ap-
plied as previously described [19,20] through 600 cycles of four
point bending of the strips with a peak strain of 3400 le.
2.4. Quantitative reverse transcriptase polymerase chain reaction
(qRT-PCR)
qRT-PCR was performed as previously described [9,19,20].
RNEasy™PlusMini Kits (Qiagen, Sussex, UK)were used to eliminate
DNA and extract RNA. First strand cDNA synthesis was performed
using SuperScriptII™ (Invitrogen, Paisley, UK). Product copy num-
bers quantiﬁed against standard curves were normalized relative
to b2-microglobulin. PCR primerswere designed using Primer3 Plus
[21]. Primer sequences (annealing TM) were as follows: Sost (60 C)
sense ACTTCAGAGGAGGCAGAAATGG, antisense CAAGGGGGAAT
CTTATCCAACTTTC; B2MG (60 C) sense AGCAAGGACTGGTCTTTC-
TATCTC, antisense CATGTCTCGATCCCACTTAA CTATC; EP1 (63 C)
sense CATCCTACTGCGCCAGGCCG, antisense CCAGGCGCTCGGTGT-
TAGGC; EP2 (60 C) sense TCGGAACG CTCCGGCTCTCA, antisense
AAGCCACTGTCGCGTCTCGC; EP3 (65 C) sense TCCCAGCAGCGGAG-
TAGGGC, antisense GCATCC CCTCCGTAGCCCCG; EP4 (62 C) sense
CCTGCAGCACGTCGGATGCT, antisense GGGCCTCTGCTGTGTGCCAA;
osteocalcin (65 C) sense CTTTGTGTCCAAGCAGGAGG, antisense
CTGAAAGCCGATGTGGTCAG.
2.5. Statistical analysis
Statistical analysis was carried out on SPSSv17 for Windows.
Comparison of two groups was by independent samples t-tests,
more than two groups were by ANOVA with Bonferroni or
Games-Howell post hoc adjustments. Data represent pooled re-
sults from 2 to 4 independent experiments (each at n = 4–6), unless
otherwise stated, and are presented as mean ± S.E.M. P < 0.05 was
considered signiﬁcant.Fig. 1. Strain-induced Sost down-regulation involves Cox-2/PG signaling. (A) Saos2
cells were subjected to strain and harvested at the indicated time points with static
controls. (B) Cells were pre-treated for 30 min with the indicated doses of NS398
before strain and harvested 8 h later with static controls. (C) Cells were treated with
vehicle or the indicated doses of PGE2 and harvested 6 h later. Sost levels were
quantiﬁed by qRT-PCR. Representative experiments shown, n = 6. NS, not signiﬁ-
cant; ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001.3. Results
3.1. Strain-induced down-regulation of Sost expression involves PG
signaling
Saos2 cells were exposed to strain and harvested at set time-
points. In each situation their Sost expression was compared to
similarly treated control cultures not exposed to strain. Signiﬁcant
Sost down-regulation was observed between 8 h and 24 h (reduced
to 52 ± 4% and 50 ± 3% of levels in the respective static controls,
P < 0.001, Fig. 1A).
Blockade of Cox-2 with the selective inhibitor NS398 dose-
dependently prevented Sost down-regulation following strain
(30 lM NS398; 96 ± 13%, P > 0.05, Fig. 1B). Exogenous addition of
PGE2 dose-dependently (Fig. 1C) down-regulated Sost expression
6 h following treatment (500 nM PGE; 32 ± 3%, P < 0.001). Levels re-
mained signiﬁcantly down-regulated 24 h later (46 ± 5%, P < 0.001).
3.2. PGE2/EP4 signaling is involved in strain-induced Sost suppression
RT-PCR established that Saos2 cells express both EP2 and EP4
receptors. EP1 and EP3 were not detected (Fig. 2A). Expression of
both EP2 and EP4 was increased by strain (200 ± 16% and
212 ± 13%, respectively, P < 0.001, Fig. 2B and C). Blockade of EP2
with 5 lM AH6809 had no signiﬁcant effect on strain-induced Sost
down-regulation (50 ± 8%, P < 0.001, Fig. 3A), whereas blockade of
EP4 with 5 lM AH23848 prevented its down-regulation by both
strain (92 ± 2%, P > 0.05, Fig. 3B) and PGE2 (107% ± 19% 24 h follow-
ing treatment, P > 0.05). Consistent with this result, 2 lM of theselective EP4 agonist TCS [22] down-regulated Sost expression
(46 ± 4%, P < 0.01, Fig. 3C).
Osteocalcin is another marker of the differentiated phenotype
reported to be up-regulated in osteoblastic cells subjected to strain
[23] or PGE2 [24]. Strain-related up-regulation of osteocalcin
expression (189 ± 16%, P < 0.001) was prevented by blockade of
Cox-2 (30 lM NS398; 114 ± 10%, P > 0.05) and EP2 (91 ± 08%,
P > 0.05, Fig. 3D), but not of EP4 (207 ± 7%, P < 0.01, Fig. 3E). PGE2
up-regulation of osteocalcin (0.5 lM PGE2; 326 ± 32%, P < 0.001)
was prevented by EP2 blockade (88 ± 15%, P > 0.05, Fig. 3F).
Fig. 2. Expression of EP2 and EP4 receptors. (A) Non-exon-spanning primers were
used to amplify EP1–4 in cDNA or gDNA positive controls from Saos2 cells. Products
were visualized by agarose gel electrophoresis with no RT or no gDNA controls. A
representative gel is shown. (B, C) Cells were exposed to strain and harvested 24 h
later with static controls. (B) EP2 and (C) EP4 levels were quantiﬁed by qRT-PCR.
⁄⁄⁄P < 0.001.
Fig. 3. Strain-induced Sost down-regulation involves EP4 signaling. Saos2 cells were pre-t
to strain and harvested 24 h later. (C) Cells were treated with 2 lM TCS and harvested
PGE2 and harvested 6 h later. (A, B, C) Sost and (D, E, F) osteocalcin levels were quantiﬁ
2452 G.L. Galea et al. / FEBS Letters 585 (2011) 2450–24543.3. Extracellular signal-regulated kinase (ERK) signaling is involved in
strain-induced Sost down-regulation
PGE2 signaling is recognized to proceed through protein kinase
C (PKC) and protein kinase A (PKA) [25]. EP4 has been reported to
activate ERK in osteoblastic cells [25]. Blockade of PKC with 1 lM
photo-activated calphostin C had no signiﬁcant effect on Sost
down-regulation (52 ± 8%, P < 0.001, Fig. 4A), but prevented osteo-
calcin up-regulation (91 ± 8%, P > 0.05, Fig. 4B). Calphostin C also
blocked osteocalcin up-regulation with 0.5 lM PGE2 (91 ± 26%,
P > 0.05, Fig. 4C). Blockade of PKA with 5 lM H89 prevented nei-
ther strain-related osteocalcin up-regulation (216 ± 17%,
P < 0.001) nor down-regulation of Sost by strain or PGE2 (50 ± 7%,
P < 0.001 and 42 ± 8%, P < 0.05, respectively) after 24 h.
Inhibition of mitogen activated protein kinase (MAPK)/ERK1/2
with 10 lM PD98059 signiﬁcantly reduced Sost levels 8 h after
treatment (54 ± 7%, P < 0.001) and prevented further strain-in-
duced down-regulation (95 ± 16%, P > 0.05 versus PD98059-treated
static controls). Sost expression in the PD98059-treated static
groups was not different from vehicle controls 24 h after treatment
(83 ± 8%, P > 0.05) and PD98059 again prevented strain-induced
Sost down-regulation (85 ± 15%, P > 0.05, Fig. 4D), but not osteocal-
cin up-regulation (268 ± 46%, P < 0.05, Fig. 4E). PD8059 also pre-
vented Sost down-regulation by PGE2 24 h following treatment
(79 ± 6%, P > 0.05, Fig. 4F).
4. Discussion
We demonstrate here that strain-related Sost down-regulation
in cells of the human osteoblastic Saos2 cell line recapitulatesreated for 30 min with (A, D) 5 lMAH6809 or (B, E) 5 lM AH23848 before exposure
6 h later. (F) Cells were treated with AH6809 30 min before treatment with 0.5 lM
ed by qRT-PCR. NS, not signiﬁcant; ⁄P < 0.05; ⁄⁄⁄P < 0.001.
Fig. 4. Strain-induced Sost down-regulation involves ERK signaling. (A, B) Saos2 cells were treated with 1 lM calphostin C 30 min before strain and harvested 24 h later. (C)
Cells were treated with 1 lM calphostin C 30 min before treatment with 0.5 lM PGE2 and harvested 6 h later. (D, E) Cells were treated with 10 lM PD98059 30 min before
strain and harvested 24 h later. (F) Cells were treated with 10 lM PD98059 30 min before treatment with 0.5 lM PGE2 and harvested 24 h later. (A, D, F) Sost and (B, C, E)
osteocalcin levels were quantiﬁed by qRT-PCR. NS, not signiﬁcant; ⁄P < 0.05; ⁄⁄⁄P < 0.001.
G.L. Galea et al. / FEBS Letters 585 (2011) 2450–2454 2453in vitro, in terms of time, that stimulated in osteocytes by loading
of the mouse tibia in vivo [9]. The time course of Sost down-regu-
lation by exposure to a short period of cyclic strain in Saos2 cells
differs from that in rat UMR-106 cells exposed to 2 h continuous
ﬂuid shear [26]. In bone in vivo Sost is osteocyte speciﬁc, therefore
its synthesis (even at low levels [4]) by Saos2 cells in vitro is likely
to reﬂect these cells’ differentiated phenotype [17,27]. This con-
trasts with its supra-physiological expression by UMR-106 cells
[4].
This study also demonstrates that, in Saos2 cells at least, strain-
induced Sost down-regulation proceeds through Cox-2 mediated
PGE2 signaling. This is consistent with the recent report that
PGE2 down-regulates Sost in UMR-106 cells via an EP2/PKA depen-
dant mechanism [28], whereas here blocking EP2 had no effect on
strain-related Sost expression. In contrast blockade of EP4 abro-
gated strain-related Sost down-regulation and a speciﬁc EP4 ago-
nist down-regulates Sost in the absence of either strain or PGE2.
This difference between the responses of the Saos2 and UMR-106
cell lines may reﬂect differences in the cells themselves and/or
temporal changes in the mechanism(s) by which Sost is regulated.
Although one of cells’ major responses to mechanical strain is PGE2
production, the response to strain involves many other mecha-
nisms [29]. For instance, strain-related PGE2 release occurs
through connexin-43 hemi-channels [30] which may result in,
and be a response to, activation of many local signaling events in
addition to those resulting from a single high dose of PGE2. Never-
theless the involvement of EP4 in strain-related Sost regulation is
consistent with reports that in vivo an EP4 selective agonist in-
duces bone formation [31] and enhances loading-related osteogen-
esis [32,33]. Mice lacking EP4, but not EP1, EP2 or EP3, are unable
to form bone in response to local infusion of PGE2 [31]. The effectof EP4 antagonists on loading-related sclerostin down-regulation
and osteogenesis now need to be determined in vivo.
Osteocalcin is also up-regulated following strain by a mecha-
nism involving PGE2 acting through the EP2 receptor. This re-
sponse was dependent on PKC, whereas Sost down-regulation
was dependent on ERK. Numerous studies have shown mechanical
signals activate ERK [34–36] but whether ERK then targets Runx2
[37,38], a major transcriptional regulator of Sost [18], remains to
be determined.
These data suggest that short periods of strain stimulate a num-
ber of signaling pathways acting on different targets to regulate
osteoblastic cell recruitment, proliferation and differentiation. Re-
lieved antagonism of Wnt signaling through Sost down-regulation
would facilitate proliferation, whereas osteocalcin up-regulation
suggests promotion of differentiation. Both processes contribute
to the actions and interactions inherent in the functional adapta-
tion of bone mass and architecture. Since these events occur prac-
tically simultaneously the targets of the diverse signaling
pathways may be different cohorts in the heterogeneous osteo-
blastic population.
The data presented here suggests that EP4-selective agonists in
pre-clinical testing [31,39] could complement sclerostin-neutraliz-
ing therapies as anabolic agents for the effective treatment of oste-
oporosis while selectively sparing other effects of PGE2 on
osteoblastic cells.
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